Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers by Ghanim B et al.
1SCIeNTIfIC RepoRts | 7: 12557  | DOI:10.1038/s41598-017-12914-2
www.nature.com/scientificreports
Intrathoracic solitary fibrous tumor 
– an international multicenter 
study on clinical outcome and novel 
circulating biomarkers
Bahil Ghanim1,2, Sebastian Hess1, Pietro Bertoglio  3, Ali Celik4, Aynur Bas4,  
Felicitas Oberndorfer5, Franca Melfi6, Alfredo Mussi3, Walter Klepetko1, Christine Pirker2, 
Walter Berger2, Imrich Harmati7, Attila Farkas7, Hendrik Jan Ankersmit1,8, Balazs Dome1,7,9, 
Janos Fillinger10, Clemens Aigner  1,11, Balazs Hegedus  1,11,12, Ferenc Renyi-Vamos7 & 
György Lang1,7
Intrathoracic solitary fibrous tumor (SFT) is a rare disease. Radical resection is the standard of care. 
However, estimating prognosis and planning follow-up and treatment strategies remains challenging. 
Data were retrospectively collected by five international centers to explore outcome and biomarkers 
for predicting event-free-survival (EFS). 125 histological proven SFT patients (74 female; 59.2%; 104 
benign; 83.2%) were analyzed. The one-, three-, five- and ten-year EFS after curative-intent surgery 
was 98%, 90%, 77% and 67%, respectively. Patients age (≥59 vs. <59 years hazard ratio (HR) 4.23, 95 
confidence interval (CI) 1.56–11.47, p = 0.005), tumor-dignity (malignant vs. benign HR 6.98, CI 3.01–
16.20, p <0.001), tumor-size (>10 cm vs. ≤10 cm HR 2.53, CI 1.10–5.83, p = 0.030), de Perrot staging  
(late vs. early HR 3.85, CI 1.65–8.98, p = 0.002) and resection margins (positive vs. negative HR 4.17, CI 
1.15–15.17, p = 0,030) were associated with EFS. Furthermore, fibrinogen (elevated vs. normal HR 4.00, 
CI 1.49–10.72, p = 0.006) and the neutrophil–to-lymphocyte-ratio (NLR > 5 vs. < 5 HR 3.91, CI 1.40– 
10.89, p = 0.009) were prognostic after univariate analyses. After multivariate analyses tumor-dignity 
and fibrinogen remained as independent prognosticators. Besides validating the role of age, tumor-
dignity, tumor-size, stage and resection margins, we identified for the first time inflammatory markers 
as prognosticators in SFT.
Intrathoracic solitary fibrous tumor (SFT) is a rare disease. In the past, the clinical management was complicated 
on the one hand by a complex and in part misleading terminology and on the other hand by the lack of diagnostic 
markers and histopathological characterization. However, progress in terms of modern pathology and genetic 
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characterization have led to a more standardized nomenclature, improved biological understanding and thus 
more precise diagnosis and clinical management1,2.
SFT is currently defined as benign or malignant tumor of mesenchymal origin3. Furthermore, with regard to 
genomic alterations, the NAB2-STAT6 gene fusion was found to be a distinct genetic hallmark of this orphan disease4. 
NAB2-STAT6 gene fusion subtypes and the mutations in the promoter of TERT demonstrated prognostic signif-
icance in SFT5,6. Furthermore, STAT6 expression detected by immunohistochemistry in tumor tissue was found 
to be an additional useful marker to verify the diagnosis of intra- and extrathoracic SFT7,8.
Despite the recent advances in molecular and pathological SFT characterization, there are no consensus 
clinical guidelines considering treatment regimens and follow-up strategies. The current standard approach is 
curative-intent surgery aiming at complete resection of the tumor regardless of its dignity. In contrast to surgery, 
the role of conventional chemotherapy, radiotherapy and targeted therapy remains to be clarified1.
Predicting outcome of SFT patients is still challenging9. Up to 80% of all SFT are histologically classified as 
benign. Nevertheless, also benign tumors can recur and transform to the malignant variant. Overall, 15–20% of 
all SFT patients develop recurrence after initial treatment1,10.
Individual histopathological parameters demonstrated only limited prognostic power in SFT11. Accordingly, 
several scores that combine histological and clinical parameters were developed to improve the prediction of 
recurrence and survival12–15. However, most information is currently derived from pathological findings and no 
reliable non-invasive prognostic biomarker exists at the moment16.
Accordingly, a better risk stratification is urgently needed to estimate the clinical course and allocate patients 
to different follow-up and treatment strategies. Consequently, besides characterizing this rare disease comprehen-
sively with regard to its clinical and pathological characteristics, we focused on analyzing the prognostic role of 
blood derived non-invasive routine markers in SFT.
Previously our study group – together with others - proved that circulating inflammatory biomarkers includ-
ing C-reactive protein (CRP), fibrinogen and the neutrophil-to-lymphocyte ratio (NLR) are prognostic and – with 
regard to fibrinogen and CRP – predictive in the setting of multimodality therapy benefit for patients suffering 
from malignant pleural mesothelioma (MPM)17–20. Furthermore, we showed that an inflammatory status has a 
negative impact on outcome of patients receiving curative pulmonary metastasectomy for metastatic colorectal 
cancer21. Thus we hypothesized that inflammatory blood derived biomarkers might also harbor prognostic power 
in patients suffering from the other primary pleural tumor besides MPM - namely intrathoracic SFT.
Results
Clinical characteristics and postoperative morbidity and mortality. In summary, 74 female (59.2%) 
and 51 male (40.8%), histological proven SFT patients were analyzed. The mean age and standard deviation was 
59 ± 12.2 years, ranging from 25 to 86 years. The most important clinical and pathological baseline characteristics 
of our study cohort are given in Table 1. Around half of the study population were never smokers (n = 56; 44.8%). 
Interestingly, 17 patients (13.6%) were suffering from other malignancies besides SFT.
The majority of all patients was treated by open surgery (n = 91; 72.8%). Median hospital stay was 7 days 
(range 2–43 days) for all patients. Patients receiving video assisted thoracic surgery (VATS) (n = 32) or robotic 
surgery (n = 2) were summarized to the VATS group (n = 34; 27.2%). The VATS group had significantly shorter 
hospital stay when compared to patients treated by open surgery (median hospital stay VATS vs. open surgery: 
5 vs. 7 days, Mann Whitney U test, p < 0.001). However, tumors treated by VATS were also significantly smaller 
(median tumor-size VATS vs. open surgery: 3.25 vs. 8.3 cm, Mann Whitney U test, p < 0.001) and always benign 
(number of malignant SFT treated by VATS vs. open surgery: 0 vs. 21, chi-square test: p = 0.002). Nevertheless, 
the proportion of R0 resection was comparable between the VATS and open surgery group (R0 resection in 31 
VATS (93.9%) vs. 81 in open surgery patients (92%), Fisher’s exact test p = 1.000) indicating, that VATS is appro-
priate to achieve R0 resection in small and benign tumors.
In 15 (12%) patients postoperative complications occurred after primary resection (postoperative bleeding 
in seven patients, arrhythmia in two patients, neurological complications in two patients, wound infection in 
one patient, pneumonia in one patient, fluidopneumothorax in one patient and finally recurrent nerve palsy in 
another patient). Postoperative complication rate tended to be higher in the open surgery group (n = 14; 15.4% 
complication rate) when compared to the VATS group (n = 1; 2.9% complication rate, Fisher exact test p = 0.067, 
type of complication: recurrent nerve palsy). 30-day mortality was present in one patient (0.8%) who had postop-
erative bleeding and deceased despite all resuscitation attempts.
In summary, 14 patients (11.2%) experienced recurrence of disease and 16 patients (12.8%) died during the 
observation period. Recurrence was treated in 9 patients (64.3%) by surgery and in 5 patients (35.7%) by chemo- 
or radiotherapy.
In general, 6 patients (4.8%) were additionally treated by systemic therapy (chemo- and/or targeted therapy), 
7 patients (5.6%) by radiotherapy and 2 patients (1.6%) by chemo- and radiotherapy besides radical resection of 
the primary tumor. The remaining 110 patients (88%) received curative-intent surgery as the single treatment.
Pathological and immunohistochemical characterization. Most patients suffered from benign SFT 
(n = 104; 83.2%). Interestingly, malignant tumors were more frequently found in older than in younger patients 
(5 patients with malignant SFT younger than mean study population age of 59 years (23.8%) vs. 16 patients older 
than 59 years (76.2%), chi-square test p = 0.028). Furthermore, malignant tumors were significantly associated 
with a tumor-size bigger than 10 cm (12 malignant tumors > 10 cm (57.1%) vs. 9 smaller than 10 cm (42.9%), 
chi-square test p = 0.005).
Of note, most recurrent patients initially suffered from malignant SFT. Nevertheless, also benign tumors 
recurred despite microscopic radical R0 resection in 6 patients (recurrence rate 8 malignant (38.1%) vs. 6 benign 
(5.8%), Fisher exact test p < 0.001). Interestingly, recurrence of benign tumors was always limited to the chest 
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(ipsilateral chest n = 4, both or contralateral chest n = 2). However, malignant SFT also recurred at extrathoracic 
sides (n = 3: brain, liver, and ilium bone).
De Perrot staging of our study cohort as well as the other major pathological characteristics are given in 
Table 1. Staging was summarized as early (de Perrot stages 0 and 1, n = 87; 69.6%) vs. late stage (de Perrot stages 
2, 3, 4 and 5, n = 34; 27.2%). In 4 patients (3.2%) information about de Perrot staging was missing.
With regards to the immunohistochemical expression profile (Fig. 1), all patients initially analyzed during 
pathological routine workup were suffering from CD34 positive tumors (n = 114; 91.2% vs. 0 CD34 negative 
tumors). Additionally, all 11 patients without retrospective CD34 scoring were tested positive for this marker 
in staining performed for the current study. In general, the major diagnostic markers of SFT besides CD34 were 
expressed by all of the studied tumors (bcl2 positive cases n = 66; 52.8% vs. 0 bcl2 negative cases, CD99 pos-
itive cases n = 34; 27.2% vs. 0 CD99 negative cases). However, it has to be pointed out, that not all diagnostic 
markers were stained in every patient during routine workup. CD34 was the most frequently stained marker 
during routine pathological workup (91.2% of the study population) indicating that most cases were diagnosed 
by CD34 positivity and general histological, microscopic SFT features. Nevertheless, bcl2 and CD99 positivity 
was observed in all of the stained cases indicating that these markers are indeed useful to confirm SFT diagnosis. 
Of note, the very recent novel diagnostic marker of SFT, namely STAT6 expression7,8 was not performed in this 
retrospective patient cohort as the overwhelming majority of cases were diagnosed prior to the identification of 
this marker.
number (%)
Gender Female  Male
74 (59.2%)  
51 (40.8%)
Smoking status
Never smoker 56 (44.8%)
Ever smoker 53 (42.4%)
Missing data 16 (12.8%)
Recurrence of disease
No recurrence 111 (88.8%)
Recurrence 14 (11.2%)
Surgery
VATS 34 (27.2%)
Open 91 (72.8%)
Additional therapy
Systemic therapy 6 (4.8%)
Radiotherapy 7 (5.6%)
Chemo-Radiotherapy 2 (1.6%)
Surgery alone 110 (88%)
Tumor dignity
Benign 104 (83.2%)
Malignant 21 (16.8%)
Tumor size
≤10 cm 86 (68.8%)
>10 cm 39 (31.2%)
Resection margins
Negative 112 (89.6%)
Positive 9 (7.2%)
Missing 4 (3.2%)
De Perrot Staging
0 49 (39.2%)
1 38 (30.4%)
2 14 (11.2%)
3 19 (15.2%)
4 1 (0.8%)
Missing 4 (3.2%)
CD34
Positive 125 (100%)
Negative 0
Bcl2
Positive 66 (52.8%)
Negative 0
Missing 59 (47.2%)
CD99
Positive 34 (27.2%)
Negative 0
Missing 91 (72.8%)
Median CRP (range) mg/dl (n = 62) 0.59 (0.2–35)
Median Fibrinogen (range) mg/dl (n = 79) 350 (200–1098)
Median NLR (range) (n = 111) 2.51 (0.93–16.38)
Table 1. Patients characteristics of the whole study cohort (n = 125). Abbreviations: video assisted thoracic 
surgery – VATS, C-Reactive Protein – CRP.
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Clinical and pathological characteristics of prognostic importance. Median EFS for all patients 
was not reached during the observation period reflecting the relative good outcome of SFT after curative–intent 
surgery. The 30-day EFS after resection was 99%, one-, three-, five- and ten-year EFS were 98%, 90%, 77% and 
67% respectively.
From the clinical and pathological baseline characteristics patients age (as continuous characteristic, HR 
1.049, CI 1.008–1.092, p = 0.019; dichotomized by mean age, ≥59 years vs. <59 years, HR 4.231, CI 1.561–11.465, 
p = 0.005), tumor-dignity (malignant vs. benign, HR 6.98, CI 3.01–16.20, p < 0.001), tumor-size (>10 cm vs. ≤ 10, 
HR 2.527, CI 1.096–5.825, p = 0.030), de Perrot staging (late vs. early de Perrot stage, HR 3.849, CI 1.651–8.975, 
p = 0.002) and surgical resection margins (positive vs. negative, HR 4.172, CI 1.147–15.169, p = 0.030) were 
found to be significantly associated with EFS after univariate survival analyses whereas gender and type of surgi-
cal approach (VATS vs. open surgery) did not influence the outcome after radical resection.
Inflammation related circulating biomarkers in the SFT cohort. Median preoperative CRP level in 
our study population was 0.59 mg/dl (range 0.02–35 mg/dl). CRP was elevated (according to the clinical cut-off 
of 0.5 mg/dl) in 36 (28.8%) and normal in 26 patients (20.8%). However, in 63 patients (50.4%) preoperative CRP 
values were missing. Median fibrinogen of all patients was 350 mg/dl (range 200–1098 mg/dl). Fibrinogen levels 
were classified as elevated (according to the clinical cut-off of 390 mg/dl) in 33 patients (26.4%) and normal in 
47 patients (37.6%). Fibrinogen levels were not available in 45 patients (36%). The median blood NLR was 2.51 
(range 0.93–16.38). In 99 patients (79.2%) the NLR was lower than 5 and in 12 (9.6%) patients the NLR was 
higher than 5. In 14 patients (11.2%) either the neutrophil and/or the lymphocyte blood count was missing and 
thus the NLR could not be calculated.
Association of inflammatory blood parameters with pathological characteristics. With regard 
to tumor-dignity, malignant SFT (non-significantly) tended to be associated with elevated fibrinogen (patients 
with malignant SFT having elevated vs. normal fibrinogen n = 11; 61.1% vs. 7; 35.5%, p = 0.052). Benign and 
malignant SFT patients did not differ significantly with regard to preoperative NLR or CRP values. Interestingly, 
patients with elevated CRP and high fibrinogen had significantly bigger tumors than patients with normal 
inflammatory parameters (median tumor-size elevated vs. normal CRP 10.15 vs. 4.95 cm, Mann Whitney U test 
p = 0.008; elevated vs. normal fibrinogen 11.0 vs. 6.5 cm, Mann Whitney U test p = 0.006). However, the differ-
ence between the high and the low NLR group with regard to tumor-size missed statistical significance (Mann 
Whitney U test p = 0.079). Furthermore, late stage of disease (late vs. early de Perrot stage) was found to be asso-
ciated with elevated fibrinogen (late stage of disease elevated vs. normal fibrinogen n = 13; 61.9% vs. 8; 38.1%, 
chi-square test p = 0.031) but no such association was found for CRP (chi-square test p = 0.855) and the NLR 
(chi-square test p = 0.175).
Figure 1. Histological features of solitary fibrous tumors. (A) The hematoxylin-eosin staining demonstrates 
relatively uniform tumor cells intimately intertwined between fibers. (B) Diffuse immunostaining of CD34 
is a histological hallmark of the disease. (C) Focal labeling of BCL2 on the SFT tumor cells. (D) Sparse Ki67 
positivity indicates the proliferating cells in the SFT tissue.
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Inflammatory circulating biomarkers as prognostic parameters in SFT. Using univariate Cox 
regression analyses, fibrinogen (elevated/ ≥ 390 mg/dl vs. normal fibrinogen, HR 4.001, CI 1.493–10.722, 
p = 0.006) and NLR ( > 5 vs. < 5 HR 3.906, CI 1.401–10.889, p = 0.009) but not CRP (elevated ≥ 0.5 mg/dl vs. 
normal CRP HR 3.185, CI 0.697–14.557, p = 0.135) were identified as prognostic blood derived biomarkers in 
SFT. The respective data are shown in Table 2 and Fig. 2, summarizing all clinical and pathological parameters of 
univariate statistical significance.
To further explore the prognostic role of inflammatory parameters in SFT, multivariate survival analyses were 
performed. Since there was a clear association between late de Perrot stage and malignant SFT, two Cox regres-
sion models including one of these parameters each were performed as illustrated in Table 3. In both multivariate 
models fibrinogen but not the NLR was an independent prognostic factor besides tumor-dignity.
Discussion
In this international multicenter study the outcome of 125 histological proven intrathoracic SFT patients treated 
by curative-intent surgery was analyzed. Of note, this relatively large SFT study demonstrates for the first time 
independent prognostic quality of a blood-derived biomarker in patients suffering from this orphan disease.
The presented SFT cohort was representative in terms of the major clinical and pathological characteristics. 
The benign subtype accounted for 83.2% of our study population. This prevalence of benign SFT was close to the 
80% found by Abu Arab1. Furthermore, as already described22,23, the malignant subtype was found to be associ-
ated with a larger tumor-size and worse outcome.
In contrast to lung cancer, only around half of all patients were smokers indicating that the pathogenesis of 
intrathoracic SFT is not as clearly related to tobacco consumption as known for lung cancer24. Similar to the liter-
ature, the prevalence of male and female SFT was almost equally distributed with a tendency towards more female 
than male cases (59.2% female). Also the mean age found in our study population was comparable to published 
data14,22,23.
In addition, age was also identified as prognostic characteristics in univariate survival analyses as shown 
before in one of the biggest SFT cohorts25. However, with regard to presence of other malignant diseases, we did 
not find a comparably high percentage of patients having other tumors besides SFT (13.6 vs. 27%) as published 
previously22. Interestingly, two patients had synchronous adenocarcinoma of the lung which was removed in both 
cases during primary SFT surgery by lobectomy. One patient died 5 years after surgery due to adenocarcinoma 
recurrence and the other patient is still alive without evidence of either disease 60 months after resection.
Importantly, our data suggest that VATS is a safe and efficient method to treat benign SFT of smaller size 
resulting in – compared to open surgery – a similar rate of tumor-free resection margins, shorter hospital stay 
and a lower complication rate. Furthermore, EFS did not differ significantly between the VATS and the open sur-
gery group demonstrating, that the long- term oncological outcome is also not negatively influenced by applying 
minimal invasive surgery in SFT.
In addition, it has to be pointed out that two thirds of all recurrent SFT patients were eligible candidates 
for surgical treatment indicating that the follow-up should be managed by an interdisciplinary team including 
pulmonologists, radio-oncologists, oncologists but also thoracic surgeons. Thus, a lung parenchyma sparing but 
radical resection should be favored to keep the possibility for redo surgery in case of recurrence (only three out of 
14 recurrent patients had extrathoracic recurrence).
Comparable to previous studies we verified the univariate prognostic value of the de Perrot staging in our 
study cohort16,26. Furthermore we proved in uni- and multivariate survival analyses, that tumor-dignity was 
prognostic independent from age, tumor-size, resection margins and the inflammatory parameters but was (as 
expected) strongly related to de Perrot stage as its power was completely lost when both pathological parameters 
were included in one multivariate model (data not shown). In addition, we showed, that tumor free resection 
margins and tumor-size impact significantly on postoperative outcome in univariate survival analyses as also 
shown before and again highlighting the central role of radical surgery in the management of SFT27,28.
For the first time, we demonstrated the independent prognostic value for preoperative fibrinogen in SFT 
receiving curative-intent surgery. Elevated fibrinogen showed a significant association with large tumor-size 
and advanced de Perrot stage. Furthermore, a – not significant but clear – tendency of higher fibrinogen in 
malignant SFT was detected. Most importantly, preoperative fibrinogen proved to be an independent prognos-
tic marker predicting outcome after curative-intent surgery (independent from age, gender, resection margins, 
tumor-dignity and de Perrot stage). Taken together, these findings indicate that patients with elevated preopera-
tive fibrinogen might suffer from a biological more aggressive SFT subtype translating to poor patient outcome. 
Characteristic Hazard ratio 95% confidence p value
Age ≥ 59 vs. < 59 years 4.231 1.561–11.465 0.005
Dignity malignant vs. benign 6.981 3.008–16.204 <0.001
Tumor size > 10 cm vs. ≤ 10 cm 2.527 1.096–5.825 0.030
De Perrot Stage late vs. early 3.849 1.651–8.975 0.002
Resection margins positive vs. negative 4.172 1.147–15.169 0.030
Fibrinogen elevated vs. normal 4.001 1.493–10.722 0.006
NLR > 5 vs. < 5 3.906 1.401–10.889 0.009
Table 2. Univariate prognostic characteristics. Abbreviations: neutrophil-to-lymphocyte – NLR.
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Figure 2. Kaplan-Meier graphs of the significant prognostic parameters. (A) Patients older than 59 years 
showed a significantly shorter event-free-survival (EFS) after curative-intent solitary fibrous tumor (SFT) 
surgery when compared to younger patients (n = 125, one-, three-, five- and ten-year 95 vs. 98; 86 vs. 94; 64 
vs 92; and 50 vs. 85% respectively, log rank test p = 0.002). (B) Malignant SFT was characterized by significant 
shorter EFS when compared to benign SFT (n = 125, one-, three-, five- and ten-year EFS 85 vs. 100; 62 vs. 95; 
44 vs. 92 and 29 vs. 74%, respectively, log rank test p < 0.001). (C) Patients with tumors bigger than 10 cm had 
the significant worse prognosis when compared to smaller tumors (n = 125, one-, three-, five- and ten-year EFS 
92 vs. 100; 85 vs. 92; and 65 vs. 82%; 52 vs. 72%, log rank test p = 0.024). (D) The impact of the de Perrot staging 
system on EFS (n = 121, one-, three-, five- and ten-year EFS late vs. early de Perrot stage: 91 vs. 100; 69 vs. 96; 
52 vs. 86 and 52 vs. 73%, respectively, log rank test p = 0.001). (E) Positive resection margins after curative-
intent surgery were associated with shortened EFS when compared to free resection lines (n = 121, one-, three-, 
five- and ten-year EFS 89 vs. 98; 78 vs. 91; 52 vs. 80; and 52 vs. 69%, log rank test p = 0.019). (F) Circulating 
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It suggests that distinct follow-up and treatment strategies after radical resection might be beneficial in this group 
of SFT patients.
Furthermore, these findings are in line with our previous experience regarding other thoracic malignancies17,19,21. 
However, in contrast to those studies mainly on mesothelioma, CRP was the only investigated inflammatory 
parameter that did not prove prognostic significance in SFT based on univariate survival analyses and thus was 
not further included in the multivariate testing. This might be at least in part explained by the relative low number 
of cases with documented CRP values (in the Italian cohort CRP was not measured at all during routine preoper-
ative check-up resulting in n = 63; 50.4% cases with missing CRP). Furthermore, it has to be mentioned that the 
median overall survival as well as the median event free survival have both not been reached during our follow-up 
period (mean follow-up of 50 months) that might influence the statistical analysis for the prognostic value of CRP 
in our cohort. Indeed, patients with normal CRP before surgery had a tendency towards longer EFS especially in 
the long term follow-up (log rank test p = 0.115, CRP high vs. low: one-, three-, five- and ten-year survival: 94 vs. 
95; 80 vs. 89; 46 vs. 89 and 31 vs. 89% respectively). This tendency might reach significance in a bigger cohort with 
more CRP values and/or longer follow-up period available. In addition, CRP values were measured by a different 
method in the Turkish cohort when compared to the rest of the study population resulting in 20 patients having 
CRP measurements performed in a different way.
Nevertheless, it has to be mentioned that patients with one or more than one characteristic missing (includ-
ing CRP, fibrinogen, NLR, de Perrot stage, and resection margins; n = 85) did not differ significantly from the 
group of patients with all parameters available (n = 40; data not shown) with regard to age, sex, tumor dignity, de 
Perrot stage, tumor size and resection margins. Thus the group of patients with missing data was assumed to be 
representative for the whole study cohort. However, statistical power was indeed negatively influenced by the low 
number of patients in case of the prognostic value for CRP.
Furthermore, CRP was found to be significantly associated with larger tumor-size. Interestingly, the val-
ues of CRP and fibrinogen were strongly correlating with each other (Pearson´s correlation coefficient 0.676, 
p < 0.001) indicating, that both acute phase response proteins have a similar biological background (data not 
shown). However, the correlation between the NLR and the two acute phase response proteins was not that strong 
(Pearson´s correlation coefficient 0.262, p = 0.047 for CRP and NLR and Pearson´s correlation coefficient 0.253, 
p = 0.029 for fibrinogen and NLR) showing that the NLR might reflect another inflammatory axis in SFT than 
CRP and fibrinogen (data not shown).
Similar to our previous findings in malignant pleural mesothelioma, elevated fibrinogen was associated with 
late stage of disease17. These findings indicate that more advanced tumors induce enhanced systemic inflamma-
tory response or alternatively produce higher amount of autocrine (inflammatory related) growth factors pro-
moting angiogenesis and proliferation, thus leading to elevated systemic inflammatory marker production by the 
liver or bone marrow. This is also suggested by comparing median tumor-size (instead of de Perrot stage) directly 
between the high and the low fibrinogen group.
Nevertheless, it has to be mentioned, that all investigated inflammatory parameters including CRP, fibrin-
ogen and the NLR are unfortunately also characterized by their low specificity since all markers are primarily 
used to detect and monitor systemic inflammation. However, all studied markers were measured before any 
surgical intervention in patients clinically judged to be fit for elective oncological surgery after exclusion of acute 
inflammatory disease. Furthermore, these markers have the advantage of being routine biomarkers which can be 
uniformly and at a low cost measured all over the world.
Inflammation plays a key role during development and progression of many malignancies. Consequently, the 
interaction between the immune system and the tumor is now also included in the recent hallmarks of cancer 
published by Hanahan and Weinberg29. The exact mechanisms that are underlying the prognostic power of sys-
temic inflammatory parameters in cancer patients are currently not fully understood. However, it is well known, 
that cancer and inflammation share many common pathways regulating important characteristics of tumor sur-
vival and progression such as angiogenesis, migration and proliferation as reviewed by Balkwill et al.30 thus also 
offering novel therapeutic targets for already established anti-inflammatory compounds in the setting of modern 
oncology.
Finally, it has to be pointed out, that the modified immune response and escape from the immune system 
by the tumor is also a novel and promising therapy target for patients suffering from different malignancies as 
reviewed by Topalian et al.31.
Taken together, we here describe for the first time a prognostic role of non-invasive inflammatory markers 
in intrathoracic SFT. These inexpensive and widely available blood derived biomarkers might provide additional 
prognostic information after curative-intent surgery in this orphan disease. Furthermore our data indicate that 
an activated systemic inflammatory response is associated with a more aggressive SFT phenotype. Of note, our 
findings suggest that these markers should be explored in extrathoracic SFT patient cohorts as well. Furthermore, 
these inflammatory biomarkers should also be explored in the setting of monitoring disease progression or recur-
rence. Last but not least, the potential normalization of these inflammatory parameters after complete surgical 
tumor removal could also be investigated in a prospective setting.
Thus we concluded that complete SFT resection results in high disease control rates. VATS showed promising 
postoperative results in small and benign tumors. However, 11% of all patients suffered from recurrent disease 
fibrinogen level had prognostic significance in SFT (n = 80, one-, three-, five- and ten-year EFS elevated vs. 
normal fibrinogen: 94 vs. 98; 72 vs. 95; 47 vs 78 and 32 vs. 69% respectively, p = 0.003). (G) The neutrophil-
to-lymphocyte-ratio was prognostic in univariate EFS analysis (n = 111, one-, three-, five- and ten-year EFS 
NLR > 5 vs. < 5: 91 vs. 99; 81 vs. 90; 28 vs. 82 and 28 vs. 70% respectively, p = 0.005).
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after curative-intent surgery. Of note, even benign tumors recurred in 6 patients despite R0 resection. Thus a 
better risk stratification is required to design adequate follow-up strategies. Fibrinogen showed independent 
prognostic value and thus might aid in planning the personalized clinical management after resection. However, 
further validation of our findings in additional, preferentially prospectively studied SFT cohorts is needed to 
establish the aforementioned parameters in clinical routine.
Patients and Methods
Patients. Initially, 162 cases were identified as SFT patients at the five participating institutes. 14 patients were 
excluded as SFT was recurrent at first admission to the participating institute and information about the primary 
presentation was not available. Five patients were excluded due to the lack of curative-intent surgery. 12 patients 
were lost to follow-up. Six patients were excluded during the histological review that revealed two MPM, one neu-
roma, one synovial sarcoma, one inflammatory pseudo-tumor and one fibrosarcoma. Finally 125 patients were 
analyzed. Retrospective data collection was approved by the national or local ethics committees (Table 4) and 
the study was conducted according to the Helsinki Declaration and the guidelines for good scientific practice of 
the respective institutions. All 125 patients received curative-intent surgery between January 1999 and February 
2016 and the diagnosis was proven by histology and immunohistochemistry at the participating centers by local 
specialized thoracic pathologists. Median follow-up after curative-intent surgery for all patients still alive during 
the observation period was 50 months (range 3–202 months) including only seven patients (5.6%) with follow-up 
less than 12 months. These seven patients had postoperative CT scan 3 months (n = 1) or 6 months (n = 5) after 
surgery available for the follow-up.
Staging was performed as previously suggested by de Perrot et al. In brief, de Perrot stage 0 and 1 are defined 
by absence of histological signs of malignancy either with a pedunculated (stage 0) or sessile (stage 1) growth 
pattern. De Perrot stage 2 and 3 are characterized by histological signs of malignancy either pedunculated (stage 
2) or sessile (stage 3). Finally, stage 4 is defined as metastatic disease14.
Malignancy was defined by the England criteria as published before taking the presence of the following his-
topathological characteristics into account: high mitotic activity, high cellularity, necrosis, cellular pleomorphism 
and hemorrhage15.
All inflammatory parameters were measured from peripheral venous blood sampled at day of admission or 
within seven days before first SFT surgery as part of preoperative routine check-up. The value closest to but 
before initial surgery was used for study purposes. CRP was measured as previously described by turbidimetric 
immunoassay32 in the same standardized way by all but not one center and the clinical cut-off (0.5 mg/dl) was 
used for dichotomizing to the elevated and normal CRP groups. CRP was measured by the nephelometric test 
only in the Turkish cohort. Fibrinogen values were determinate in all participating centers by the Claus method33 
and considered as elevated when higher than 390 mg/dl. Finally, the NLR was calculated by dividing the blood 
Department Ethic committee approval number Number of patients
National Koranyi Institute, Budapest, Hungary Hungarian Medical Research Council (52614–4/2013/EKU) 35
Division of Thoracic Surgery, University of Pisa, Italy Bioethics Committee, University of Pisa (791/2015) 28
Division of Thoracic Surgery, Medical University of 
Vienna, Austria
Medical University of Vienna Ethic Committee 
(1671/2014) 24
Department of Thoracic Surgery, Gazi University School 
of Medicine, Ankara, Turkey Gazi University Ethic Committee 129/2015 20
Department of Thoracic Surgery, National Institute of 
Oncology - Semmelweis University, Budapest, Hungary
Hungarian Medical Research Council (52614–
4/2013/EKU) 18
Table 4. Participating centers and ethical approvals.
Model 1 (n = 71) Model 2 (n = 67)
Number of events 17 16
Number without event 54 51
Characteristic HR 95% CI p HR 95% CI p
Age ≥ 59 vs. < 59 years 1.61 0.47–5.55 0.452 1.74 0.49–6.11 0.390
Dignity malignant vs. benign 4.66 1.22–17.80 0.024
Tumor size > 10 cm vs. ≤ 10 cm 2.47 0.64–9.63 0.192 2.09 0.56–7.83 0.276
De Perrot Stage late vs. early 4.31 0.95–19.49 0.058
Resection margins positive vs. negative 2.99 0.45–19.99 0.258 2.98 0.46–19.09 0.250
Fibrinogen elevated vs. normal 4.55 1.20–17.17 0.026 4.44 1.11–17.69 0.035
NLR > 5 vs. < 5 2.50 0.49–12.88 0.274 4.11 0.71–23.76 0.114
Table 3. Multivariate survival analyses. Abbreviations: neutrophil-to-lymphocyte – NLR. Model 1 multivariate 
cox regression including following characteristics: patient age, tumor dignity, tumor size, surgical resection 
margins, fibrinogen and the NLR opposed to. Model 2 consisting of age, tumor size, de Perrot stage instead of 
tumor dignity, surgical resection margins, fibrinogen and the NLR.
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neutrophil by the blood lymphocyte count. The NLR was considered high when bigger than 5 as published before 
for MPM by our group19.
The mean age (mean 59 ± 12.2 years) was used to dichotomize patients into the two age groups. With regard to 
tumor-size we employed the same cut-off (10 cm) as published before for intrathoracic SFT using the pathological 
report as source of information23.
Statistical analyses. Metric data is always given as median and corresponding range if not otherwise indi-
cated. Mann-Whitney U Test was utilized to compare the means of non-parametric distributed data. Unpaired 
t-test was used for parametric distributed data. Pearson’s chi-square test and Fisher’s exact test were performed as 
applicable to investigate the association between categorical factors. Event-free-survival (EFS) is reported in all 
survival analyses and was calculated as time between first surgery and death/recurrence or time from first surgery 
to last follow-up in patients still alive and without any evidence of disease. Survival analyses were performed 
by the Kaplan-Meier method and the log rank test. Furthermore, the Cox-regression was utilized to calculate 
the hazard ratios (HR) and corresponding confidence intervals (CI) for uni- and multivariate survival analyses. 
Multivariate survival analyses included the characteristics of univariate prognostic value. Two models were calcu-
lated since tumor-dignity and de Perrot stage were strongly correlating with each other. The two models consisted 
of 1) age (dichotomized by the mean age of 59 years), tumor-dignity (malignant vs. benign), tumor-size (>10 cm 
vs. ≤10 cm), resection margins (positive vs. negative), fibrinogen (high vs. low) and NLR (>5 vs. <5); and 2) age 
(dichotomized by the mean age of 59 years), de Perrot staging (late vs. early), tumor-size (>10 cm vs. ≤10 cm), 
resection margins (positive vs. negative), fibrinogen (high vs. low) and NLR (>5 vs. <5). All statistical analyses 
were calculated with SPSS Statistics 21 package (IBM®). P values are always given as two-sided and were consid-
ered statistically significant below 0.05.
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